Healthy DonorsNCT07821736
Impact of Leukoreduction Timing on Plasma Citrullinated Histone H3 (H3cit) Dynamics and Red Blood Cell Storage Lesions
A study testing H3Cit in people with Healthy Donors, run by Assiut University at 1 site in Egypt.
Trial summary
Impact of Leukoreduction Timing on Plasma Citrullinated Histone H3 (H3cit) Dynamics and Red Blood Cell Storage Lesions To measure H3cit levels immediately after filtration on Days 0, 1, 3, and 5. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Donors
- What is being tested?
- H3Cit
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Nov 2026to 1 Dec 2028
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- • Standard whole blood units collected from healthy voluntary donors who meet the national blood transfusion service fitness criteria (age 18-60 years, body weight ≥50 kg).
- Collection Volume \& Container: Standard unit volume (450 ± 45 mL) collected into closed bag systems with additive/anticoagulant solution (CPDA-1).
- Thermal Storage Chain: Blood units maintained continuously within standard blood bank temperature limits (2 C to 6C )from collection until the end of the storage period.
- Baseline Hematological Parameters: Normal baseline hematological profile immediately post-collection (Hemoglobin ≥12.5g dl)
Who cannot join
- Donor Clinical Factors: Donors with a history of acute or chronic inflammatory conditions, active infections, autoimmune diseases, or those who ingested anti-inflammatory/antiplatelet medications (e.g., NSAIDs, aspirin) within 14 days prior to donation.
- Technical Collection Complications: Phlebotomy draw time exceeding 12 minutes, difficult venipuncture, or units displaying macro-clots or excessive lipemia post-collection.
- Storage Excursions \& Bag Damage: Any blood unit subjected to cold-chain temperature violations outside 2-6C, physical damage, or system breaches/leaks.
- Transfusion-Transmitted Infections (TTI): Units testing reactive for screening markers, including HBsAg, Anti-HCV, Anti-HIV-1/2, or Syphilis
- Donor Clinical Factors: Donors with a history of acute or chronic inflammatory conditions, active infections, autoimmune diseases, or those who ingested anti-inflammatory/antiplatelet medications (e.g., NSAIDs, aspirin) within 14 days prior to donation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Impact of Leukoreduction Timing on Plasma Citrullinated Histone H3 (H3cit) Dynamics and Red Blood Cell Storage Lesions To measure H3cit levels immediately after filtration on Days 0, 1, 3, and 5. To measure H3cit levels during storage at mid-storage and shelf-life end To correlate H3cit levels with standard blood storage markers
Read the detailed description
Packed red blood cells (PRBCs) are the most commonly transfused blood component and play a critical role in treating anemia, trauma, and surgical patients. However, during refrigerated storage, PRBCs undergo a sequence of biochemical, metabolic, and structural changes collectively referred to as the "storage lesion." These changes include depletion of adenosine triphosphate (ATP) and 2,3-diphosphoglycerate (2,3-DPG), glucose utilization, lactate production, pH changes, potassium loss, oxidative stress, increased free hemoglobin release, and morphological alterations such as decreased deformability and microparticle formation. Such changes can impair erythrocyte function and survival following transfusion, particularly in critically ill patients and those requiring massive transfusion Studies have demonstrated that markers of NETs increase during RBC storage and are significantly higher in non-leukoreduced units compared to leukoreduced units(5) Specifically, in canine models, day 42 non-leukoreduced units contained approximately 1000-fold more cell-free DNA than leukoreduced units, with significantly higher Cit-H3 levels Leukoreduction, the removal of white blood cells from blood products, is performed to reduce transfusion reactions and immunomodulation. Pre-storage leukoreduction has been shown to prevent cytokine accumulation during storage and reduce the risk of febrile nonhemolytic transfusion reactions and TRALI The timing of leukoreduction is critical, as pre-storage filtration prevents the accumulation of leukocyte-derived bioactive substances that occur during storage, whereas post-storage filtration does not Importantly, universal leukoreduction has been associated with an 83% decrease in TRALI rates, highlighting the clinical significance of leukocyte removal Neutrophil extracellular traps (NETs) are web-like structures composed of DNA, histones, and neutrophil granular proteins extruded from activated neutrophils. NETs have been implicated in cytotoxicity, thrombosis, and autoimmunity, and they play a role in the pathogenesis of transfusion-related acute lung injury (TRALI) Citrullinated histone H3 (Cit-H3) is a specific marker of NETosis, as NET formation requires histone citrullination by peptidylarginine deiminase 4 (PAD4) Given the established role of NETs in transfusion-related complications and the potential for Cit-H3 to serve as a quality marker, this study aims to evaluate Cit-H3 levels in stored RBC units and assess its correlation with storage duration and leukoreduction timing. The findings could provide insights into optimizing storage conditions and improving transfusion outcomes through better identification and mitigation of storage lesions
- Conditions
- Healthy Donors
- Being tested
- H3Cit
- Keywords
- Leukoreduction timing on H3Cit
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
H3CitOther
To measure H3cit levels during storage at mid-storage and shelf-life end
| Study group | Role | What they receive |
|---|---|---|
| Leukoreduction Timing on H3Cit | Experimental | Not described Receives: Other: H3Cit |
What is being measured
The primary outcome is the main question the study is designed to answer.
To measure H3cit levels immediately after filtration
Measured: on Days 0, 1, 3, and 5.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2026
- Study start1 Nov 2026 (estimated)
- Primary completion1 May 2028 (estimated)
- Study completion1 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy DonorsStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mayar Medhat Hamed Thabet, Assiut University
- Investigators
- Mariam Ezzat Abdallah, Assistant professor, Study director, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07821736
- Sponsor's protocol ID
- Leukoreduction Timing on H3cit
- Status last verified
- Sep 2026
- First submitted
- 10 Sep 2026
- Last updated
- 16 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No